Serum Institute clarifies report on COVID-19 vaccine launch in India in 10 weeks


NEW DELHI: Serum Institute of India, which has partnered with Oxford University to produce COVID-19 vaccine, has clarified that Indian government has granted it permission to only manufacture the vaccine and stockpile it for future use, reported live mint.


Covishield, the Oxford University-Astra Zeneca vaccine candidate, will be commercialized once trials are proven successful and requisite regulatory approvals are in place, Pune-based Serum Institute has said.

Serum Institute’s clarification came after reports mentioned that the Oxford COVID-19 vaccine may be launched in 73 days.


Phase-3 trials for Oxford-AstraZeneca vaccine are underway and only once the vaccine is proven immunogenic and efficacious, Serum Institute will confirm its availability officially, the world’s largest vaccine manufacturer said.

Meanwhile, medical research body ICMR will soon launch a COVID-19 vaccine website which will provide information related to the COVID-19 vaccine development in India and abroad, with majority of the updates in several regional languages in addition to English.